Taylor J, Tartaglia J, Rivière M, Duret C, Languet B, Chappuis G, Paoletti E
Virogenetics Corporation, Troy, NY.
Dev Biol Stand. 1994;82:131-5.
This paper presents data derived from safety and efficacy studies of ALVAC-based rabies and feline leukemia virus (FeLV) vaccine candidates in target species. Inoculation of the ALVAC-RG recombinant was well tolerated in all species including humans and very young dogs. Protection induced in dogs against rabies challenge was long-lasting and could be elicited in the face of high levels of maternally-derived neutralizing antibody. Parenteral inoculation of cats with an ALVAC-FeLV recombinant was safe and induced protection against persistent infection following oro-nasal FeLV challenge.
本文介绍了基于安卡拉痘病毒（ALVAC）的狂犬病和猫白血病病毒（FeLV）候选疫苗在目标物种中的安全性和有效性研究数据。ALVAC-RG重组疫苗在包括人类和幼犬在内的所有物种中都具有良好的耐受性。犬接种该疫苗后对狂犬病攻击的保护作用持久，且在存在高水平母源中和抗体的情况下仍可诱导产生保护。对猫进行ALVAC-FeLV重组疫苗的非肠道接种是安全的，并能在经口鼻途径感染FeLV后诱导产生针对持续性感染的保护作用。
